Free tool
FAERS Monitor: Qlonilik
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 221094 or its brand name (Qlonilik, Clonidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,651
Serious
3,859
68% of reports
Hospitalization
1,611
Death reported
915
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypertension762
- headache711
- off label use658
- pain638
- fatigue634
- hypersensitivity549
- drug ineffective523
- nausea476
- infusion related reaction442
- hepatic enzyme increased436
- joint swelling425
- rash411
- dyspnoea386
- prescribed overdose374
- diarrhoea369
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 22 |
| 2009 | 8 |
| 2010 | 65 |
| 2011 | 111 |
| 2012 | 102 |
| 2013 | 67 |
| 2014 | 72 |
| 2015 | 110 |
| 2016 | 117 |
| 2017 | 244 |
| 2018 | 236 |
| 2019 | 221 |
| 2020 | 261 |
| 2021 | 329 |
| 2022 | 617 |
| 2023 | 649 |
| 2024 | 894 |
| 2025 | 895 |
| 2026 | 608 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,508 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prescribed overdoseSignal | 374 | 73.3 | 66.4 | 26,121 |
| infusion related reactionSignal | 442 | 25.0 | 22.8 | 10,114 |
| hepatic enzyme increasedSignal | 436 | 23.9 | 21.9 | 9,535 |
| hypertensionSignal | 762 | 13.4 | 12.6 | 8,816 |
| joint swellingSignal | 425 | 13.1 | 12.0 | 4,768 |
| hypersensitivitySignal | 549 | 11.0 | 10.2 | 5,031 |
| headacheSignal | 711 | 4.2 | 3.9 | 1,798 |
| painSignal | 638 | 3.9 | 3.6 | 1,394 |
| rashSignal | 411 | 3.5 | 3.2 | 751 |
| fatigueSignal | 634 | 3.0 | 2.8 | 894 |
| off label useSignal | 658 | 2.8 | 2.6 | 791 |
| dyspnoeaSignal | 386 | 2.5 | 2.3 | 368 |
| nauseaSignal | 476 | 2.2 | 2.1 | 338 |
| diarrhoeaSignal | 369 | 2.1 | 1.9 | 226 |
| drug ineffective | 523 | 1.5 | 1.4 | 85 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.